Chicago Partners Investment Group LLC Boosts Holdings in Humana Inc. $HUM

Key Points

• Chicago Partners Investment Group LLC increased its stake in Humana Inc. by 97.1% during Q2, now owning 2,560 shares worth approximately $607,000.
• Humana's recent quarterly earnings report showed an EPS of $6.27, falling short of estimates, with revenue rising 9.6% year-over-year to $32.39 billion.
• The company announced a quarterly dividend of $0.885 per share, reflecting an annualized yield of 1.2%, with a payout ratio currently at 27.17%.

Chicago Partners Investment Group LLC raised its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 97.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,560 shares of the insurance provider's stock after acquiring an additional 1,261 shares during the quarter. Chicago Partners Investment Group LLC's holdings in Humana were worth $607,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Humana by 63.9% during the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock worth $31,000 after buying an additional 46 shares in the last quarter. Zions Bancorporation National Association UT purchased a new stake in shares of Humana during the first quarter worth about $37,000. Ransom Advisory Ltd purchased a new stake in shares of Humana during the first quarter worth about $66,000. Transamerica Financial Advisors LLC grew its holdings in shares of Humana by 1,027.6% during the first quarter. Transamerica Financial Advisors LLC now owns 327 shares of the insurance provider's stock worth $87,000 after buying an additional 298 shares in the last quarter. Finally, Tower View Wealth Management LLC purchased a new stake in shares of Humana during the second quarter worth about $88,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Up 3.9%

Shares of HUM stock opened at $295.20 on Wednesday. The stock has a market cap of $35.50 billion, a price-to-earnings ratio of 22.66, a price-to-earnings-growth ratio of 1.66 and a beta of 0.42. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35. The firm's 50 day moving average price is $281.27 and its two-hundred day moving average price is $258.60.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same period in the previous year, the firm posted $6.96 earnings per share. The company's revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. On average, analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, September 26th. Humana's payout ratio is presently 27.17%.

Analyst Upgrades and Downgrades

HUM has been the subject of a number of recent analyst reports. Wells Fargo & Company boosted their target price on shares of Humana from $344.00 to $347.00 and gave the company an "overweight" rating in a report on Tuesday, October 7th. Barclays lowered their target price on shares of Humana from $315.00 to $245.00 and set an "equal weight" rating for the company in a report on Friday, October 3rd. Sanford C. Bernstein boosted their target price on shares of Humana from $269.00 to $341.00 and gave the company an "outperform" rating in a report on Friday, September 5th. Morgan Stanley lowered their target price on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a report on Thursday, July 31st. Finally, Truist Financial set a $300.00 target price on shares of Humana in a report on Tuesday, October 14th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $297.58.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.